106sek
1,0 %
Date:2026-06-12Time:18:00:00Latest report:Q1-2026List:First NorthTicker:NXTCL
Market Cap:134 msekEnterprise Value:90 msekNet Sales:10,8 msekEarnings:-37,5 msekEmployees:0ISIN:SE0009723125

Ratios

10-year key figure history for NextCell Pharma turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for NextCell Pharma with index and moving average MA50 and MA200.

Stockprice:1,06
MA50:1,19
MA200:1,08
Price/MA200:-2,1 %
RSI (14):42,4
Price/MA50:-11,0 %

Description

NextCell Pharma is a Swedish clinical-stage cell therapy company developing treatments for immune-mediated diseases, with the company's most recent candidate being a type 1 diabetes candidate. The company's platform, NXTCL™, is designed to enable cell therapies with consistent efficacy, scalable manufacturing and the potential to change the course of the disease. NextCell is headquartered in Huddinge.

Biotechnology